{"id":"https://openalex.org/W4200522731","doi":"https://doi.org/10.1182/blood-2021-147907","title":"Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia","display_name":"Updated Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W4200522731","doi":"https://doi.org/10.1182/blood-2021-147907"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-147907","doi":"https://doi.org/10.1182/blood-2021-147907","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-147907","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040299600","display_name":"Mark C. Walters","orcid":"https://orcid.org/0000-0002-6515-4559","observed_orcids":["https://orcid.org/0000-0002-6515-4559"]},"institutions":[{"id":"https://openalex.org/I4210135903","display_name":"UCSF Benioff Children's Hospital","ror":"https://ror.org/03hwe2705","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135903"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark C. Walters","raw_affiliation_strings":["Division of Hematology, UCSF Benioff Children's Hospital Oakland, Oakland, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, UCSF Benioff Children's Hospital Oakland, Oakland, CA","institution_ids":["https://openalex.org/I4210135903"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076642923","display_name":"Angela R. Smith","orcid":"https://orcid.org/0000-0002-8870-5579","observed_orcids":["https://orcid.org/0000-0002-8870-5579"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela R. Smith","raw_affiliation_strings":["Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037299848","display_name":"Gary John Schiller","orcid":"https://orcid.org/0000-0002-7508-3467","observed_orcids":["https://orcid.org/0000-0002-7508-3467"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gary J. Schiller","raw_affiliation_strings":["Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006845399","display_name":"Erica B. Esrick","orcid":"https://orcid.org/0000-0002-8373-6026","observed_orcids":["https://orcid.org/0000-0002-8373-6026"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erica B. Esrick","raw_affiliation_strings":["Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056346259","display_name":"David A. Williams","orcid":"https://orcid.org/0000-0001-7057-6863","observed_orcids":["https://orcid.org/0000-0001-7057-6863"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David A. Williams","raw_affiliation_strings":["Division of Hematology/Oncology, Boston Children's Hospital, Boston,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, Boston Children's Hospital, Boston,","institution_ids":["https://openalex.org/I1288882113"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040127808","display_name":"Tatiana E. Gogoleva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140998","display_name":"Sangamo BioSciences (United States)","ror":"https://ror.org/046dwx283","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tatiana Gogoleva","raw_affiliation_strings":["Sangamo Therapeutics, Brisbane, CA, Brisbane, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sangamo Therapeutics, Brisbane, CA, Brisbane, CA","institution_ids":["https://openalex.org/I4210140998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015754915","display_name":"Didier Rouy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140998","display_name":"Sangamo BioSciences (United States)","ror":"https://ror.org/046dwx283","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Didier Rouy","raw_affiliation_strings":["Sangamo Therapeutics, Brisbane, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sangamo Therapeutics, Brisbane, CA","institution_ids":["https://openalex.org/I4210140998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038664397","display_name":"Bettina M. Cockroft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140998","display_name":"Sangamo BioSciences (United States)","ror":"https://ror.org/046dwx283","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bettina M. Cockroft","raw_affiliation_strings":["Sangamo Therapeutics, Brisbane, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sangamo Therapeutics, Brisbane, CA","institution_ids":["https://openalex.org/I4210140998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043649821","display_name":"Gregory M. Vercellotti","orcid":"https://orcid.org/0000-0003-1324-0831","observed_orcids":["https://orcid.org/0000-0003-1324-0831"]},"institutions":[{"id":"https://openalex.org/I130238516","display_name":"University of Minnesota","ror":"https://ror.org/017zqws13","country_code":"US","type":"education","lineage":["https://openalex.org/I130238516"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory M. Vercellotti","raw_affiliation_strings":["Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN","institution_ids":["https://openalex.org/I130238516"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"3974","last_page":"3974"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10554","display_name":"Hemoglobinopathies and Related Disorders","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.027699999511241913,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10878","display_name":"CRISPR and Genetic Engineering","score":0.010099999606609344,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/transfusion-dependent-beta-thalassemia","display_name":"transfusion-dependent beta-thalassemia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/zinc-finger-nucleases","display_name":"zinc finger nucleases","score":0.8109999895095825},{"id":"https://openalex.org/keywords/bcl11a","display_name":"BCL11A","score":0.9419999718666077},{"id":"https://openalex.org/keywords/fetal-hemoglobin","display_name":"fetal hemoglobin","score":0.8159999847412109},{"id":"https://openalex.org/keywords/autologous-hematopoietic-stem-cells","display_name":"autologous hematopoietic stem cells","score":0.8379999995231628},{"id":"https://openalex.org/keywords/genome-editing","display_name":"genome editing","score":0.6930000185966492},{"id":"https://openalex.org/keywords/myeloablative-conditioning","display_name":"myeloablative conditioning","score":0.7409999966621399},{"id":"https://openalex.org/keywords/busulfan","display_name":"busulfan","score":0.8370000123977661},{"id":"https://openalex.org/keywords/cd34-cells","display_name":"CD34+ cells","score":0.7549999952316284},{"id":"https://openalex.org/keywords/gene-therapy","display_name":"gene therapy","score":0.40299999713897705},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5960000157356262}],"concepts":[{"id":"https://openalex.org/C2776317666","wikidata":"https://www.wikidata.org/wiki/Q2496436","display_name":"Fetal hemoglobin","level":4,"score":0.5996788144111633},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.520578920841217},{"id":"https://openalex.org/C35802184","wikidata":"https://www.wikidata.org/wiki/Q204773","display_name":"Zinc finger nuclease","level":5,"score":0.5173277854919434},{"id":"https://openalex.org/C109159458","wikidata":"https://www.wikidata.org/wiki/Q919283","display_name":"Haematopoiesis","level":3,"score":0.4989931583404541},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.4836903214454651},{"id":"https://openalex.org/C2780914630","wikidata":"https://www.wikidata.org/wiki/Q914952","display_name":"Cord blood","level":2,"score":0.46481141448020935},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42570921778678894},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3931758999824524},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3749125003814697},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34933048486709595},{"id":"https://openalex.org/C24284526","wikidata":"https://www.wikidata.org/wiki/Q204785","display_name":"Zinc finger","level":4,"score":0.17949244379997253},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.12086740136146545},{"id":"https://openalex.org/C172680121","wikidata":"https://www.wikidata.org/wiki/Q26513","display_name":"Fetus","level":3,"score":0.09945499897003174},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09507164359092712},{"id":"https://openalex.org/C2779234561","wikidata":"https://www.wikidata.org/wiki/Q11995","display_name":"Pregnancy","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-147907","doi":"https://doi.org/10.1182/blood-2021-147907","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-147907","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.46000000834465027,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1965520671","https://openalex.org/W128192250","https://openalex.org/W2356390869","https://openalex.org/W2466322957","https://openalex.org/W25899969","https://openalex.org/W2138546400","https://openalex.org/W2065210043","https://openalex.org/W2350490050","https://openalex.org/W2414295837","https://openalex.org/W2794172480"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Persistently":[2],"elevated":[3,541],"fetal":[4],"hemoglobin":[5],"(HbF)":[6],"can":[7],"ameliorate":[8],"transfusion-dependent":[9],"beta":[10,43],"thalassemia":[11],"(TDT)":[12],"(Musallam":[13],"et":[14],"al":[15],".,":[16],"2012).":[17],"BCL11A":[18,33,67,72,107,215,433],"is":[19,34,86,116,148,491,507,1129],"a":[20,35,136,149,285,599,1046,1124,1155,1164,1185,1194],"repressor":[21],"of":[22,32,40,59,63,93,113,129,153,159,214,270,290,296,319,353,359,416,443,473,497,567,793,936,953,968,983,1012,1038,1081,1151,1160,1181,1190,1231],"\u03b3-globin":[23],"expression":[24,73,120,520],"and":[25,74,157,191,200,234,256,325,462,540,595,1127],"HbF":[26,41,76,119,407,448,480,519,542,553,605],"production":[27,77],"in":[28,42,78,121,141,161,437,500,521,538,582,604,641,721,763,840,1023,1143,1154,1163,1169,1184,1193],"adult":[29,162],"erythrocytes.":[30],"Down-regulation":[31],"therapeutic":[36],"strategy":[37],"for":[38,176,197,232,236,467,516,1003,1061,1069,1111,1213,1234],"induction":[39],"hemoglobinopathies.":[44],"In":[45],"pre-clinical":[46],"studies":[47],"with":[48,164,189,203,207,365,369,405,420,523,598,1226],"human":[49],"hematopoietic":[50,388,531],"stem":[51],"cells":[52,80,96,199,441],"(HSCs),":[53],"zinc":[54],"finger":[55],"nuclease":[56],"(ZFN)-mediated":[57],"disruption":[58],"the":[60,64,106,154,211,294,303,309,326,329,346,357,360,471,474,479,501,551,571,577,583,589,1109,1170,1218],"GATA-binding":[61,212],"region":[62,213],"intronic":[65],"erythroid-specific":[66],"enhancer":[68],"(BCL11A":[69],"ESE)":[70],"decreased":[71],"increased":[75,517],"erythroid":[79,123,518],"without":[81],"disrupting":[82],"multi-lineage":[83],"hematopoiesis.":[84],"ST-400":[85,130,160,218,254,297,310,366,506,578],"an":[87,268,508,790,933,950,965,980,1009,1035,1078,1199],"investigational":[88,1219],"cell":[89,173],"therapy":[90],"product":[91,219,514,1222],"comprised":[92],"autologous":[94,512,1220,1232],"CD34+":[95,198],"that":[97,127,299,409,588],"have":[98,135,252,257],"undergone":[99],"high-precision,":[100],"ZFN-mediated":[101],"ex":[102,509,1242],"vivo":[103,1243],"editing":[104],"at":[105,177,432,570],"gene":[108],"ESE":[109,434],"target.":[110],"The":[111,144,217,281,317,580,1105],"aim":[112],"this":[114,1122],"study":[115,152,331],"to":[117,229,245,305,308,314,350,411,425,494,548,561,576,999,1029,1100,1102,1216,1228],"induce":[118],"edited":[122],"cells.":[124],"We":[125],"hypothesized":[126],"infusion":[128,298],"after":[131,293,333,606],"myeloablative":[132,223,534],"conditioning":[133],"would":[134],"favorable":[137],"benefit":[138],"risk":[139],"profile":[140],"TDT.":[142,524],"Methods:":[143],"Thales":[145],"trial":[146],"(NCT03432364)":[147],"Phase":[150],"1/2":[151],"safety,":[155],"tolerability":[156],"efficacy":[158,235],"subjects":[163,227,242,385,528],"TDT,":[165],"defined":[166],"as":[167,348,574,1123],"receiving":[168],"\u22658":[169],"annual":[170],"red":[171],"blood":[172,439],"transfusion":[174,468],"episodes":[175],"least":[178],"2":[179,549],"consecutive":[180],"years":[181,238,247],"before":[182],"enrollment.":[183],"Leukapheresis":[184],"was":[185,220,300,321,591,596],"performed":[186],"following":[187,222,363,533,544],"mobilization":[188,1230],"G-CSF":[190,1227],"plerixafor.":[192],"Autologous":[193,1238],"collections":[194],"were":[195,228,435,451,459,464],"enriched":[196],"then":[201,1240],"transfected":[202],"mRNA":[204],"encoding":[205],"ZFNs":[206],"binding":[208],"sites":[209],"flanking":[210],"ESE.":[216],"infused":[221,527,586],"busulfan":[224],"conditioning.":[225],"Six":[226],"be":[230,264,306],"monitored":[231],"safety":[233,1047],"3":[237],"post-infusion.":[239],"Results:":[240],"Five":[241],"(age":[243],"18":[244],"36":[246],"old,":[248],"average":[249,269,552],"28":[250],"years)":[251],"completed":[253],"manufacturing":[255],"been":[258,375],"infused.":[259,265],"No":[260,371],"additional":[261],"patients":[262,522,585],"will":[263,1119],"Subjects":[266],"received":[267,328],"7.3":[271],"x":[272],"10":[273],"6":[274],"CD":[275],"34+":[276],"cells/kg":[277],"(high":[278,455,486],"low":[279,456,487,495],"4.5-11.4).":[280],"first":[282],"subject":[283],"experienced":[284],"serious":[286],"adverse":[287],"event":[288,318],"(SAE)":[289],"hypersensitivity":[291,320],"soon":[292],"initiation":[295],"considered":[301],"by":[302,345,557],"investigator":[304,347],"related":[307],"infusion,":[311],"most":[312],"likely":[313],"dimethylsulfoxide":[315],"(DMSO).":[316],"successfully":[322],"medically":[323],"managed":[324],"patient":[327],"full":[330],"dose":[332],"brief":[334],"interruptions.":[335],"One":[336],"other":[337],"treatment":[338,364],"emergent":[339],"SAE":[340],"(opioid":[341],"withdrawal)":[342],"occurred,":[343],"assessed":[344],"unrelated":[349],"ST-400.":[351],"As":[352,415],"03":[354,417],"May":[355,418],"2021,":[356,419],"majority":[358],"AEs":[361],"reported":[362],"are":[367,482],"consistent":[368],"myeloablation.":[370],"clonal":[372],"expansion":[373],"has":[374,1116],"observed":[376],"from":[377,423,559],"monitoring":[378],"on-target":[379,428,536],"indel":[380],"clones":[381],"longitudinally.":[382],"All":[383,525],"five":[384,445,526],"had":[386,529,555],"prompt":[387],"reconstitution":[389,532],"(average":[390],"ANC":[391],"recovery":[392,399],"day":[393,400],"+18":[394],"[range":[395,402],"14-24":[396],"days];":[397],"platelet":[398],"+29":[401],"19-44":[403],"days]),":[404],"increasing":[406],"fraction":[408],"contributed":[410],"stable":[412],"total":[413],"hemoglobin.":[414],"follow-up":[421],"ranging":[422],"17.6":[424],"27.3":[426],"months,":[427],"DNA":[429],"insertions-deletions":[430],"(indels)":[431],"present":[436],"peripheral":[438],"mononuclear":[440],"(PBMCs)":[442],"all":[444],"subjects.":[446],"Peak":[447],"levels":[449,481,496,543,554],"achieved":[450],"23.5":[452],"+-":[453,484],"11.4%":[454],"35.9-6.9%)":[457],"but":[458],"not":[460,465,1120],"sustained,":[461],"thus":[463],"sufficient":[466],"independence.":[469],"At":[470],"time":[472],"latest":[475],"visit":[476],"(65-117":[477],"weeks),":[478],"7.7":[483],"4.1%":[485],"13.5-2%).":[488],"This":[489],"decline":[490],"presumably":[492],"due":[493],"long-term":[498],"progenitors":[499],"final":[502],"drug":[503],"product.":[504],"Conclusions:":[505],"vivo,":[510],"ZFN-edited":[511],"HSC":[513],"candidate":[515],"rapid":[530],"conditioning,":[535],"indels":[537],"PBMCs":[539],"HSCGT.":[545],"After":[546],"1":[547,609],"years,":[550],"declined":[556],"64%":[558],"peak":[560],"last":[562],"visit,":[563],"which":[564],"necessitated":[565],"resumption":[566],"PRBC":[568],"transfusions":[569],"same":[572],"rate":[573],"prior":[575,1215],"therapy.":[579],"data":[581],"5":[584],"indicate":[587],"procedure":[590],"generally":[592],"well":[593],"tolerated":[594],"associated":[597],"significant":[600],"albeit":[601],"transient":[602],"increase":[603],"reconstitution.":[607],"Figure":[608,610],"1.":[611],"Disclosures":[612],"Walters:":[613],"Ensoma,":[614],"Inc.:":[615,707],"Consultancy;":[616,619,622,668,714,731,739,744,918,920],"Vertex":[617],"pharmaceuticals:":[618],"AllCells,":[620],"Inc:":[621,624,861],"BioLabs,":[623],"Consultancy.":[625,927],"Smith:":[626],"Astellas":[627,1200],"Gene":[628],"Therapies:":[629],"Current":[630,638,718,760,837,1138,1140,1149,1158,1177,1179,1188],"Employment.":[631],"Schiller:":[632],"ASH":[633],"foundation:":[634],"Other:":[635,941,958,973,988,995,1017,1043,1086],"Chair-unpaid;":[636],"Pfizer:":[637],"equity":[639,719,761,838,1141],"holder":[640,720,762,839,1142,1150,1159,1180,1189],"publicly-traded":[642,722,764,841,1144],"company,":[643,765,842,1157,1166,1187],"Research":[644,648,653,658,662,670,673,676,679,683,686,690,693,696,701,709,725,728,736,741,746,750,753,756,767,772,776,781,784,798,803,806,811,814,817,820,823,826,830,833,843,849,854,857,862,865,869,872,875,879,882,886,893,899,902,905,908,912,915,1072,1133,1203,1207],"Funding;":[645,654,659,671,674,677,680,684,687,691,694,697,726,729,737,742,747,751,754,757,773,782,785,804,807,812,815,818,821,824,827,831,834,855,858,863,866,870,873,876,880,883,887,894,900,903,906,909,913,916,1073,1204],"Sanofi:":[646],"Honoraria,":[647,661,700,708,766,848,889],"Funding,":[649,663,702,710,768,777,799,844,850],"Speakers":[650,664,703,711,769,778,800,845,851,890,922],"Bureau;":[651,665,704,712,770,779,801,846,852,891],"Ambit:":[652],"Biomed":[655],"Valley":[656],"Discoveries:":[657],"Kite/Gilead:":[660],"Kaiser":[666],"Permanente:":[667],"MedImmune:":[669],"Mateon:":[672],"Cyclacel:":[675],"PrECOG:":[678],"Novartis:":[681,921,1006],"Consultancy,":[682,699,749,759,775,787,836,1202],"Onconova:":[685],"Eli":[688],"Lilly:":[689],"Samus:":[692],"Takeda:":[695],"Jazz:":[698],"Stemline":[705],"Therapeutics,":[706],"Pharma:":[713],"Johnson":[715],"&":[716,733,1058,1093],"Johnson:":[717],"company;":[723],"Sangamo:":[724],"Sellas:":[727],"Ono:":[730],"Leukemia":[732],"Lymphoma":[734],"Society:":[735],"AstraZeneca:":[738],"Ariad:":[740],"Incyte:":[743,786],"Regimmune:":[745],"Ono-UK:":[748],"Bio:":[752,868],"Elevate:":[755],"Amgen:":[758],"Tolero:":[771],"Agios:":[774],"Trovagene:":[780],"Karyopharm:":[783],"Membership":[788,931,948,963,978,1007,1033,1044,1076],"on":[789,932,949,964,979,1008,1034,1045,1077],"entity's":[791,934,951,966,981,1010,1036,1079],"Board":[792,935,952,967,982,1011,1037,1080],"Directors":[794,937,954,969,984,1013,1039,1082],"or":[795,938,955,970,985,1014,1040,1083],"advisory":[796,939,956,971,986,1015,1041,1048,1084],"committees,":[797,940,957,972,987,1016,1042,1085],"Geron:":[802],"Genentech-Roche:":[805],"Gamida":[808],"Cell":[809],"Ltd.:":[810],"FujiFilm:":[813],"Forma:":[816],"Delta-Fly:":[819],"Deciphera:":[822],"Daiichi-Sankyo:":[825],"Constellation":[828],"Pharmaceuticals:":[829],"Celator:":[832],"BMS/Celgene:":[835],"Astellas:":[847],"Arog:":[853],"Actuate:":[856],"Actinium":[859],"Pharmaceuticals,":[860],"Abbvie:":[864],"Bluebird":[867,1115],"Boehringer-Ingleheim:":[871],"Cellerant:":[874],"CTI":[877],"Biopharma:":[878],"Janssen:":[881],"Kura":[884],"Oncology:":[885],"Pharmacyclics:":[888],"Millennium:":[892],"National":[895],"Marrow":[896],"Donor":[897],"Program:":[898],"NIH:":[901],"Onyx:":[904],"Pharmamar:":[907],"UC":[910],"Davis:":[911],"UCSD:":[914],"Evidera:":[917],"NCI:":[919],"Bureau.":[923],"Esrick:":[924],"bluebird":[925,1074,1103],"bio:":[926,1075],"Williams:":[928],"Beam":[929],"Therapeutics:":[930,1032,1137,1148,1176],"Scientific":[942,960,974],"Advisory":[943,975,991,1026,1090],"Board;":[944,976,992],"Emerging":[945],"Therapy":[946],"Solutions:":[947],"Chief":[959],"Chair;":[961],"Geneception:":[962],"BioMarin:":[977],"Insertion":[989,1087],"Site":[990,1088],"Alerion":[993],"Biosciences:":[994],"Co-founder":[996,1055],"(now":[997],"licensed":[998,1096],"Avro":[1000],"Bio,":[1001],"potential":[1002,1110],"future":[1004,1062,1112],"milestones/royalties);":[1005],"Steering":[1018],"Committee,":[1019],"Novartis":[1020],"ETB115E2201":[1021],"(eltrombopag":[1022],"aplastic":[1024],"anemia).":[1025],"fees":[1027],"donated":[1028],"NAPAAC.;":[1030],"Orchard":[1031],"board":[1049],"(SAB):":[1050],"SAB":[1051],"position":[1052],"ended":[1053],"05/20/2021.":[1054],",":[1056],"Patents":[1057,1092],"Royalties:":[1059,1094],"Potential":[1060],"royalty/milestone":[1063,1113],"income,":[1064],"X-SCID.":[1065],"Provided":[1066],"GMP":[1067],"vector":[1068],"clinical":[1070,1125],"trial,":[1071],"Analysis":[1089],"Board,":[1091],"BCH":[1095,1128],"certain":[1097],"IP":[1098],"relevant":[1099],"hemoglobinopathies":[1101],"bio.":[1104],"current":[1106],"license":[1107],"includes":[1108],"income.":[1114],"indicated":[1117],"they":[1118],"pursue":[1121],"program":[1126],"negotiating":[1130],"return":[1131],"of,":[1132],"Funding.":[1134,1208],"Gogoleva:":[1135],"Sangamo":[1136,1147,1175],"Employment,":[1139,1178],"company.":[1145,1196],"Rouy:":[1146],"individual":[1152,1182],"stocks":[1153,1183],"privately-held":[1156,1165,1186,1195],"stock":[1161,1191],"options":[1162,1192],"Ended":[1167],"employment":[1168],"past":[1171],"24":[1172],"months.":[1173],"Cockroft:":[1174],"Vercellotti:":[1197],"Mitobridge,":[1198],"Company:":[1201],"CSL":[1205],"Behring:":[1206],"OffLabel":[1209],"Disclosure:":[1210],"busulfan:":[1211],"used":[1212,1225],"myeloablation":[1214],"infusing":[1217],"HSPC":[1221,1233,1239],"(ST-400)":[1223],"plerixafor:":[1224],"enhance":[1229],"collection":[1235],"via":[1236],"leukapheresis.":[1237],"undergo":[1241],"m":[1244]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}